$19.04
+0.24
(+1.28%)▲
Market Capitalization | $703.5M |
Revenue TTM | $215.2M |
EBITDA | $61.3M |
Earnings Per Share (EPS) | $1.44 |
PE Ratio | 13.06 |
Profit Margin | 25.53% |
Quarterly Earnings Growth YOY | 0.0% |
Return On Equity TTM | 16.42% |
0.0%
Downside
Day's Volatility :3.4%
Upside
3.4%
41.96%
Downside
52 Weeks Volatility :46.07%
Upside
7.08%
Period | Entrada Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 12.6% | -6.4% | 0.0% |
6 Months | 17.97% | 0.7% | 0.0% |
1 Year | 52.32% | 10.9% | 0.0% |
3 Years | -34.14% | 10.2% | -21.2% |
What analysts predicted
Upside of 34.3%
Insights on Entrada Therapeutics, Inc.
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 67.2%
Sell
Neutral
Buy
Entrada Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Entrada Therapeutics, Inc. | 9.61% | 17.97% | 52.32% | -34.14% | -20.5% |
Regeneron Pharmaceuticals, Inc. | -19.29% | -22.98% | -6.09% | 16.5% | 106.01% |
Biontech Se | 6.62% | 28.33% | 24.67% | -65.3% | 465.36% |
Alnylam Pharmaceuticals, Inc. | -12.52% | 67.25% | 57.65% | 33.12% | 110.8% |
Vertex Pharmaceuticals Incorporated | -3.08% | 3.32% | 31.85% | 151.49% | 110.78% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Entrada Therapeutics, Inc. | 13.06 | 13.06 | NA | 1.03 | 0.16 | 0.07 | NA | 11.93 |
Regeneron Pharmaceuticals, Inc. | 18.25 | 18.25 | 1.1 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Entrada Therapeutics, Inc. | Buy | $703.5M | -20.5% | 13.06 | 25.53% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.1B | 106.01% | 18.25 | 33.61% |
Biontech Se | Buy | $27.1B | 465.36% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.6B | 110.8% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.1B | 110.78% | 32.84 | -4.51% |
Baker Bros Advisors LP
Mpm Asset Management, LLC
5AM Venture Management, LLC
T. Rowe Price Associates, Inc.
FMR Inc
BlackRock Inc
entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.
Organization | Entrada Therapeutics, Inc. |
Employees | 177 |
CEO | Mr. Dipal Doshi |
Industry | Services |